 | Up a level |
Stenner, Frank; Rothschild, Sacha I; Betticher, Daniel; Caspar, Clemens; Morant, Rudolf; Popescu, Razvan; Rauch, Daniel; Huber, Urs; Zenhäusern, Reinhard; Rentsch, Cyrill; Cathomas, Richard (2017). Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry. (In Press). Clinical genitourinary cancer Elsevier 10.1016/j.clgc.2017.08.003
Salzberg, Marc; Rochlitz, Christoph; Morant, Rudolf; Thalmann, George; Pedrazzini, Augusto; Roggero, Enrico; Schönenberger, Astrid; Knuth, Alexander; Borner, Markus (2007). An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer. Onkologie, 30(7), pp. 355-60. Basel: Karger 10.1159/000102452
Salzberg, Marc; Borner, Markus; Bauer, Jean-Alexandre; Morant, Rudolf; Rauch, Daniel; Rochlitz, Christoph (2006). Trastuzumab (Herceptin) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder: report on 7 patients. European journal of cancer, 42(15), pp. 2660-1. Amsterdam: Elsevier 10.1016/j.ejca.2006.06.009
Glaus, Agnes; Boehme, Christel; Thürlimann, Beat; Ruhstaller, Thomas; Hsu, Shu-Fang; Morant, Rudolf; Senn, Hans-Jörg; von Moos, Roger (2006). Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment. Annals of oncology, 17(5), pp. 801-806. Oxford: Oxford University Press 10.1093/annonc/mdl030
Schmid, Hans-Peter; Morant, Rudolf; Bernhard, Jürg; Maibach, Rudolf; Swiss Group for Clinical Cancer Research, (SAKK) (2003). Prostate specific antigen doubling time as auxiliary end point in hormone refractory prostatic carcinoma. European urology, 43(1), pp. 28-30. Amsterdam: Elsevier 10.1016/S0302-2838(02)00539-0
